![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » FDA Grants Ivax Final Approval for Generic Neurontin
FDA Grants Ivax Final Approval for Generic Neurontin
The FDA recently granted Ivax final approval for gabapentin tablets in 600- and 800-mg dosage strengths.
Gabapentin is the generic version of Pfizer's seizure medication, Neurontin.
U.S. sales for Neurontin in 600- and 800-mg tablets were $1.1 billion in 2004, according to IMS Health data. Ivax is presently litigating whether its gabapentin products infringe a patent held by Pfizer. A trial in the U.S. District Court of New Jersey has not yet been scheduled.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct